Lupin Q3 net profit jumps 43% to Rs 335 cr on strong US sales
Top Stories
- Trouble mounts for Sreesanth as Mumbai cops gather more evidence
- SIT to seek Supreme Court guidance on Maya Kodnani death penalty issue
- Tamil Nadu police bans Yasin Malik-linked pro-Eelam public meeting
- Kings XI Punjab end IPL 2013 campaign with a win
- Narendra Modi: India losing sheen as agricultural nation
Drug firm Lupin today posted a 42.57 per cent rise in consolidated net profit at Rs 335.2 crore for the third quarter ended December 31, 2012, on the back of strong sales in the US market.
The Mumbai-headquartered firm had posted a net profit of Rs 235.1 crore during the same period of previous fiscal.
Consolidated net sales of the company rose by 37.62 per cent to Rs 2,465.9 crore during the third quarter, as against Rs 1,791.7 crore during the same period of 2011- 12 fiscal, Lupin said in a statement.
During the quarter under review, the company's formulation sales in the US and Europe grew by 60 per cent to Rs 1,082.9 crore as against Rs 6,76.3 crore during the corresponding period of previous fiscal.
"We had a record quarter driven by strong operating performance and growth in the US. Importantly, we continue to improve on margins consistently," Lupin Ltd Managing Director Kamal K Sharma said.
The company, which said it is the market leader in 22 products out of the 43 products marketed in the US generics market, launched five new products in the US during the third quarter.
During the quarter, the company's India formulations business grew by 14 per cent posting net revenues of Rs 570.8 crore compared to Rs 501.1 crore during the same period of previous fiscal.
The company said sales in Japan grew by 48 per cent to Rs 365.8 crore during the quarter compared to Rs 246.8 crore in the corresponding period of 2011-12 fiscal. "Japan now contributes 15 per cent to Lupin's consolidated revenues," it added.
During the period under review, the com pany's South African business, Pharma Dynamics clocked revenues of Rs 83.1 crore, representing a growth of 43 per cent, over the same period of previous fiscal.
... contd.
Now, 15-year-old girls can buy morning after emergency contraceptive pills in US
US govt sues Novartis Pharmaceuticals for health care fraud
'New norms won't lead to rise in drug prices for a year'
Dr Reddy's launches generic Zoledronic Acid injection in USEditors’ Pick
- Quake-hit and shaken, Bhaderwah spends nights in the open
- UP blast accused dies on way to jail, govt wanted to drop case against him
- Former civil aviation secy changes mind, seeks airport security exemption as EC
- BCCI suspects Gujarat players in other teams were also approached
- Mumbai police say they too may seek custody of arrested pacer
- Chhattisgarh 'encounter' leaves 8 villagers dead, no Maoist link yet
- Destitute, orphan students outclass rest in Andhra Class 10 exams
